Alpha Diagnostic International, Inc. Anti-Human Beta-Amyloid 1-40/42 antiserum BAM402-S

Anti-Human Beta-Amyloid 1-40/42 antiserum General Information Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. One of the most important and initial step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) r SugApplications Most Antibodies are tested by ELISA and Western. Additional applications, such as IHC or IP may have been tested and will be listed in the product data sheets or published research papers using our products. Typically, antibodies are tested against the SugSecAntibodies http://4adi.com/comm erce/ccc2480-seconda ry-antibodies-rabbit .htm SpeciesReactivity Human SugNegativeControl Non-immune Rabbit IgG Cat# 20009-1 Form Antiserum Unpurified SugPositiveControl Recombinant or naturally purified proteins or cells of tissues expressing the protein under study can be used as positive controls for Western or IHC. Please review the ?General Information? tan under Product overview section. Control or blocking peptid Antigen full length, synthetic -1-40 (designated BAM402-P control peptides) conjugated to BSA (1) SpCrossreactivity The human BAM402-P peptide sequence (40 aa) has high degree of homology with human and murine -Amyloid (1-40 aa) and -Amyloid (1-42 aa). Weak crossreactivity is also observed with -Amyloid (1-28 aa) and -Amyloid (12-28 aa). However, no crossreaction is observed with CGRP. Full length -Amyloid (1-40 aa, and 1-42 aa) peptides can be used as positive controls and to block antibody activity. For research use only, not for diagnostic or therapeutic use.